S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility

J Hepatol. 2012 Nov;57(5):1097-109. doi: 10.1016/j.jhep.2012.04.041. Epub 2012 May 30.


S-adenosyl-L-methionine (SAMe; AdoMet) is an important, metabolically pleiotropic molecule that participates in multiple cellular reactions as the precursor for the synthesis of glutathione and principle methyl donor required for methylation of nucleic acids, phospholipids, histones, biogenic amines, and proteins. SAMe synthesis is depressed in chronic liver disease and so there has been considerable interest in the utility of SAMe to ameliorate disease severity. Despite encouraging pre-clinical data confirming that SAMe depletion can exacerbate liver injury and supporting a hepatoprotective role for SAMe therapy, to date no large, high-quality randomised clinical trials have been performed that establish clinical utility in specific disease states. Here, we offer an in-depth review of the published scientific literature relating to the physiological and pathophysiological roles of SAMe and its therapeutic use in liver disease, critically assessing implications for clinical practice and offering recommendations for further research.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Chronic Disease
  • Evidence-Based Medicine
  • Humans
  • Liver Diseases / drug therapy*
  • Liver Diseases / metabolism
  • S-Adenosylmethionine / metabolism
  • S-Adenosylmethionine / therapeutic use*
  • Severity of Illness Index


  • S-Adenosylmethionine